Durability As The New Standard In Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

(MENAFN- News Direct) -kGTyPW jmTMzx"> Austin, Texas, United States, October 22nd, 2026, NewsDirect

Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time. That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury. Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee.

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time?

One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is built around the...

Read More>>

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid marketing engagement with IBN

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

The latest news and updates relating to RGNT are available in the company's newsroom at

Corporate Communications

IBN

Austin, Texas

512.354.7000 Office

[email protected]

Contact

IBN

[email protected]

MENAFN22102026005728012573ID1111852247